Evidence map›Paper›PMID 35296014›Full record

ArticleFrontiers in oncology2022

Tryptophan Metabolites as Biomarkers for Esophageal Cancer Susceptibility, Metastasis, and Prognosis.

Yun Chen, Jianliang Chen, Dainian Guo, Peixuan Yang, Shuang Chen, Chengkuan Zhao, Chengcheng Xu, Qiuzhen Zhang, Chaoxian Lin, Shilong Zhong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Cancer pathogenesis and therapy · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Yun ChenDepartment of Pharmacy, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Jianliang ChenClinical Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, China.
Dainian GuoDepartment of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China.
Peixuan YangHealth Management Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Shuang ChenDepartment of Pharmacology, Shantou University Medical College, Shantou, China.
Chengkuan ZhaoDepartment of Pharmacy, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Chengcheng XuDepartment of Pharmacy, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Qiuzhen ZhangDepartment of Pharmacy, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Chaoxian LinDepartment of Pharmacology, Shantou Chaonan Minsheng Hospital, Shantou, China.
Shilong ZhongDepartment of Pharmacology, Shantou University Medical College, Shantou, China.
Shuyao ZhangDepartment of Pharmacy, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Jinan University · CNShantou University · CNCancer Hospital of Shantou University Medical College · CNFirst Affiliated Hospital of Shantou University Medical College · CNGuangdong Provincial People's Hospital · CNShantou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Perturbation of tryptophan (TRP) metabolism contributes to the immune escape of cancer; however, the explored TRP metabolites are limited, and their efficacy in clarifying the susceptibility and progression of esophageal cancer (EC) remains ambiguous. Our study sought to evaluate the effects of the TRP metabolic profile on the clinical outcomes of EC using a Chinese population cohort; and to develop a risk prediction model targeting TRP metabolism. Method: A total of 456 healthy individuals as control subjects and 393 patients with EC who were followed up for one year as case subjects were enrolled. Quantification of the plasma concentrations of TRP and its metabolites was performed using HPLC-MS/MS. The logistic regression model was applied to evaluate the effects of the clinical characteristics and plasma metabolites of the subjects on susceptibility and tumor metastasis events, whereas Cox regression analysis was performed to assess the overall survival (OS) of the patients. Results: Levels of creatinine and liver enzymes were substantially correlated with multiple metabolites/metabolite ratios in TRP metabolism, suggesting that hepatic and renal function would exert effects on TRP metabolism. Age- and sex-matched case-control subjects were selected using propensity score matching. Plasma exposure to 5-HT was found to be elevated 3.94-fold in case subjects (N = 166) compared to control subjects (N = 203), achieving an AUC of 0.811 for predicting susceptibility event. Subsequent correlation analysis indicated that a higher plasma exposure to 5-HIAA significantly increased the risk of lymph node metastasis (OR: 2.16, Conclusion: This study provides a pivotal basis for targeting endogenous TRP metabolism as a potential therapeutic intervention.

Indexed as

circulating biomarkeresophageal cancermetastasisprognosissusceptibilitytryptophan metabolism

Identifiers

PMID35296014
PMCPMC8918692
OpenAlexW4226191527

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.